Four-Year Patient Follow-up Data Support Safety and Effectiveness of Endologix's Powerlink System; Three Presentations Highlight
February 17 2006 - 7:08PM
Business Wire
Endologix, Inc. (Nasdaq:ELGX) today announced that four-year
patient follow-up data from the Company's Powerlink(R) System
pivotal clinical trial supports the safety and effectiveness of the
Powerlink as an endoluminal stent graft (ELG) in protecting
patients from rupture of the abdominal aortic aneurysm (AAA).
Rodney A. White, M.D., Professor of Surgery at UCLA School of
Medicine and Chief of Vascular Surgery at Harbor-UCLA Medical
Center, presented the data at the International Congress XIX on
Endovascular Interventions. Two additional presentations featuring
AAA treatment with the Powerlink System were also presented at this
meeting. Dr. White's presentation, "Four-year Results of the
Pivotal U.S. Multicenter Trial for the Endologix Powerlink
Endograft for EVAR," presented follow-up from 192 patients treated
with the Powerlink System in Endologix's pivotal clinical trial.
The mean follow-up patient time was 36.1 months with a range of .03
- 62.0 months. Dr. White reported that only 26 patients from the
follow-up group required a secondary procedure and most were
treated for Type II endoleak, indicating that the need for the
secondary procedure was not device related. Dr. White further noted
that all cohorts treated with the Powerlink System experienced
aneurysm sac diameter and volume reductions, shrinking of the
aneurysm sac around the device, and minimal change in the length of
the aorta from the most distal renal artery to aortic bifurcation.
The Powerlink's column strength and unique long main body may
directly influence the remodeling of the aneurismal aorta. Of the
192 patients followed for 48 months: -- 97.9% of patients were free
from AAA-related mortality -- There were no reported aneurysm
ruptures -- There were no ePTFE graft material failures -- There
were no cobalt chromium stent graft failure or fatigue -- There was
only one late conversion that occurred at one year The second
presentation, "Does Preoperative AAA Size Influence Sac Regression
and Classical Remodeling the Powerlink System?" by James Williams,
M.D., and Michael Brown, M.D., concluded: -- Treatment of AAA (less
than or equal to 50mm) provided nearly complete sac regression to
near normal aortic measurement within the first three years post
treatment. -- Patients with aneurysms (greater than 50mm)
experienced a larger percentage reduction in mean sac diameter and
greater straightening of sac angulation over three years than
patients with smaller aneurysms. A third topic, "Endovascular
Aneurysm Repair (EVAR) With Suprarenal Versus Infrarenal Fixation:
A Controlled Study of Renal Effects," submitted by Shane Parmer,
M.D., and Jeffrey P. Carpenter, M.D., both from the University of
Pennsylvania School of Medicine, was presented. In an analysis in
which 79 patients received suprarenal fixation and 47 received
infrarenal fixation, the authors concluded: -- Suprarenal fixation
does not result in a significant increase in acute renal events,
renal impairment or alterations in blood pressure control in
comparison to infrarenal fixation. "The International Congress
provides an excellent forum to highlight the positive attributes of
our Powerlink System, supporting our objective of driving physician
acceptance for our ELG," said Paul McCormick, Endologix president
and chief executive officer. "These presentations reinforced
earlier findings about the long-term durability of our Powerlink
ELG and this procedure's benefit in treating aortic aneurysm
disease." About Endologix Endologix, Inc. develops and manufactures
minimally invasive treatments for vascular diseases. Endologix's
Powerlink System is an endoluminal stent graft (ELG) for treating
abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of
the aorta, the largest artery in the body, resulting in a
balloon-like enlargement. Once AAA develops, it continues to
enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 75%, making it the thirteenth leading cause of death
in the U.S. In October 2004, Endologix received approval to market
the Powerlink in the U.S. Additional information can be found on
Endologix's Web site at www.endologix.com. Except for historical
information contained herein, this news release contains
forward-looking statements, the accuracy of which are necessarily
subject to risks and uncertainties, including risks related to
changes in regulatory requirements, and product liability claims,
all of which are difficult or impossible to predict accurately and
many of which are beyond the control of Endologix, all as more
fully described in the risk factors and other matters set forth in
the Company's Annual Report on Form 10-K for the year ended
December 31, 2004, and the Company's other filings with the
Securities and Exchange Commission.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jul 2023 to Jul 2024